Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
VTUS's Cash to Debt is ranked higher than
100% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. VTUS: No Debt )
VTUS' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Interest Coverage No Debt
VTUS's Interest Coverage is ranked higher than
98% of the 462 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 90.51 vs. VTUS: No Debt )
VTUS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: -3.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -139.18
VTUS's ROE (%) is ranked lower than
59% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. VTUS: -139.18 )
VTUS' s 10-Year ROE (%) Range
Min: -139.18   Max: -99.46
Current: -139.18

-139.18
-99.46
ROA (%) -120.60
VTUS's ROA (%) is ranked lower than
60% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. VTUS: -120.60 )
VTUS' s 10-Year ROA (%) Range
Min: -2734.34   Max: -92.71
Current: -120.6

-2734.34
-92.71
ROC (Joel Greenblatt) (%) -355071.43
VTUS's ROC (Joel Greenblatt) (%) is ranked lower than
61% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. VTUS: -355071.43 )
VTUS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -425025   Max: -25692.31
Current: -355071.43

-425025
-25692.31
» VTUS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

VTUS Guru Trades in Q1 2013

Jim Simons 95,676 sh (New)
Paul Singer 1,787,158 sh (+45.63%)
» More
Q2 2013

VTUS Guru Trades in Q2 2013

Jim Simons 190,933 sh (+99.56%)
Paul Singer 1,787,158 sh (unchged)
» More
Q3 2013

VTUS Guru Trades in Q3 2013

Paul Singer 1,787,158 sh (unchged)
Jim Simons 131,900 sh (-30.92%)
» More
Q4 2013

VTUS Guru Trades in Q4 2013

Paul Singer 1,787,158 sh (unchged)
Jim Simons 108,738 sh (-17.56%)
» More
» Details

Insider Trades

Latest Guru Trades with VTUS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-06-30 Sold Out 0.02%$4.27 - $13.25 $ 1.05-89%0
George Soros 2012-03-31 New Buy0.02%$7.99 - $11.83 $ 1.05-88%120000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.70
VTUS's P/B is ranked higher than
95% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. VTUS: 0.70 )
VTUS' s 10-Year P/B Range
Min: 0   Max: 2.9
Current: 0.7

0
2.9
EV-to-EBIT 0.20
VTUS's EV-to-EBIT is ranked higher than
99% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. VTUS: 0.20 )
VTUS' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 0.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.70
VTUS's Price/Net Cash is ranked higher than
99% of the 219 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.70 vs. VTUS: 0.70 )
VTUS' s 10-Year Price/Net Cash Range
Min: 1.52   Max: 11.53
Current: 0.7

1.52
11.53
Price/Net Current Asset Value 0.70
VTUS's Price/Net Current Asset Value is ranked higher than
98% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.80 vs. VTUS: 0.70 )
VTUS' s 10-Year Price/Net Current Asset Value Range
Min: 1.52   Max: 11.53
Current: 0.7

1.52
11.53
Price/Tangible Book 0.70
VTUS's Price/Tangible Book is ranked higher than
95% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. VTUS: 0.70 )
VTUS' s 10-Year Price/Tangible Book Range
Min: 1.51   Max: 11.35
Current: 0.7

1.51
11.35
Earnings Yield (Greenblatt) 468.90
VTUS's Earnings Yield (Greenblatt) is ranked higher than
98% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. VTUS: 468.90 )
VTUS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 5588.4
Current: 468.9

0
5588.4
Forward Rate of Return (Yacktman) -476.12
VTUS's Forward Rate of Return (Yacktman) is ranked lower than
58% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. VTUS: -476.12 )
VTUS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -476.12

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:V7B.Germany
Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company. The Company is engaged in the late-stage clinical development of gastrointestinal products in areas of unmet need, anal fissures, and fecal incontinence.
» More Articles for VTUS

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide